Den europeiske union -
norsk -
EMA (European Medicines Agency)
brukinsa
beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastiske midler - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).
Norge -
norsk -
Statens legemiddelverk
toujeo 300 e/ ml
orifarm as - insulin glargin - injeksjonsvæske, oppløsning i ferdigfylt penn - 300 e/ ml
Norge -
norsk -
Statens legemiddelverk
zyprexa 5 mg
orifarm as - olanzapin - tablett, drasjert - 5 mg
Norge -
norsk -
Statens legemiddelverk
zyprexa 7.5 mg
farmagon - olanzapin - tablett, drasjert - 7.5 mg
Norge -
norsk -
Statens legemiddelverk
zyprexa 10 mg
farmagon - olanzapin - tablett, drasjert - 10 mg
Norge -
norsk -
Statens legemiddelverk
zyprexa 10 mg
orifarm as - olanzapin - pulver til injeksjonsvæske, oppløsning - 10 mg